TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23619901

Group type: EXPERIMENTAL
Intervention: ICG-augmented diode laser therapy (ICG + DL) at a total dose of 4 mg/kg body weight
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) therapy before and after ICG administration (ICG + IPL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Flashlamp-pumped pulsed dye laser (FPDL)
Number of subjects: 15
Study: 19763572

Group type: EXPERIMENTAL
Intervention: High-dose HAIC (5-FU, 500 mg/m² on days 1-3 and cisplatin, 60 mg/m² on day 2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Low-dose HAIC (5-FU, 170 mg/m² and cisplatin, 7 mg/m² on days 1-5)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: High-dose HAIC
Number of subjects: 68

Group type: COMPARATOR
Intervention: Low-dose HAIC
Number of subjects: 68
Study: 18447211

Group type: EXPERIMENTAL
Intervention: Needle-pricking therapy combined with spinal massage
Number of subjects: 93

Group type: COMPARATOR
Intervention: Azulfidine (medication group)
Number of subjects: 93
Study: 16392100

Group type: EXPERIMENTAL
Intervention: Unilateral neck exploration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bilateral neck exploration
Number of subjects: 100
Study: 14738669

Group type: EXPERIMENTAL
Intervention: Endo-GIA Universal 6-row stapler (USSC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: ETS-Flex 6-row stapler (Ethicon)
Number of subjects: 100
Study: 11192138

Group type: EXPERIMENTAL
Intervention: Amlodipine (once daily, morning or evening)
Number of subjects: 1507
Study: 9159299

Group type: EXPERIMENTAL
Intervention: Sodium ramping (linear from 155 mEq/L to 140 mEq/L)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard dialysis (steady dialysate sodium of 140 mEq/L)
Number of subjects: 23
Study: 8439075

Group type: EXPERIMENTAL
Intervention: Nebulized L‐Adrenaline and placebo (IM)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nebulized saline and placebo (IM)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nebulized saline and dexamethasone (IM)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nebulized L‐Adrenaline and dexamethasone (IM)
Number of subjects: 66
Study: 3530030

Group type: EXPERIMENTAL
Intervention: Birch pollen preparation (n = 14) with doses up to 1.4 X 10(6) biologic units per day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Birch pollen preparation (n = 14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 30
Study: 31854207

Group type: EXPERIMENTAL
Intervention: Varenicline (n=42)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (n=39)
Number of subjects: 81
Study: 30552261

Group type: EXPERIMENTAL
Intervention: Subjective selective carious tissue removal
Number of subjects: 115

Group type: COMPARATOR
Intervention: Objective selective removal with a self-limiting bur (Polybur, Komet)
Number of subjects: 115
Study: 27255560

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% plus 8 mg dexamethasone
Number of subjects: 200

Group type: COMPARATOR
Intervention: bupivacaine 0.5%
Number of subjects: 200
Study: 26597415

Group type: EXPERIMENTAL
Intervention: DPP‐based lifestyle intervention
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 92
Study: 23919573

Group type: EXPERIMENTAL
Intervention: Family Nurse Partnership programme
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1600
Study: 20429838

Group type: EXPERIMENTAL
Intervention: Proteomic profiling using off‐line strong cation exchange fractionation with RP‐LC‐ESI‐MS/MS
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Proteomic profiling
Number of subjects: 54
Study: 18761784

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg continuously once daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: Levocetirizine 5 mg on-demand
Number of subjects: 62
Study: 15893525

Group type: EXPERIMENTAL
Intervention: Similarity judgments, short‐term memory and long‐term learning tasks among semi‐nomadic tribesmen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Categorical Perception effects
Number of subjects: 0
Study: 13678869

Group type: EXPERIMENTAL
Intervention: Candesartan (target dose 32 mg once daily)
Number of subjects: 2548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2548

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2548
Study: 11130294

Group type: EXPERIMENTAL
Intervention: recombinant human GH (hGH) at a dose of 0.125 U.kg‐1.wk‐1 for four weeks and 0.25 U.kg‐1.wk‐1 thereafter
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: recombinant human GH (hGH)
Number of subjects: 9
Study: 8656490

Group type: EXPERIMENTAL
Intervention: Interlocking nail
Number of subjects: 116

Group type: COMPARATOR
Intervention: Ender nail
Number of subjects: 116
Study: 1626114

Group type: EXPERIMENTAL
Intervention: Methacholine (Mch) test
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nebulized ultrasonic distilled water (NUDW) test
Number of subjects: 24
Study: 6384817

Group type: EXPERIMENTAL
Intervention: 5 X 10(6) IU of natural alpha interferon daily for 6 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 24
Study: 30130145

Group type: EXPERIMENTAL
Intervention: Nothophaeocryptopus gaeumannii population in New Zealand
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: Nothophaeocryptopus gaeumannii populations in North and South Islands
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: Nothophaeocryptopus gaeumannii isolates
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: Nothophaeocryptopus gaeumannii introduction
Number of subjects: 2085
Study: 30454052

Group type: EXPERIMENTAL
Intervention: Fluralaner plus moxidectin (Bravecto® Plus)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Fipronil (Frontline®)
Number of subjects: 707
Study: 26670987

Group type: EXPERIMENTAL
Intervention: Compression Stockings (CS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Regular Socks
Number of subjects: 19
Study: 25040192

Group type: COMPARATOR
Intervention: Sofosbuvir + ribavirin (POSITRON)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Sofosbuvir + ribavirin (FUSION)
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Sofosbuvir + ribavirin (FISSION)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Sofosbuvir + ribavirin + interferon (NEUTRINO)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Pegylated interferon + ribavirin (FISSION)
Number of subjects: 994
Study: 22205314

Group type: EXPERIMENTAL
Intervention: Iodine supplementation (various doses from 0 to 2000 μg/d)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: High-iodine intervention groups (1500-2000 μg)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 400 μg I supplementation
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 500-2000 μg I supplementation
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 20150398

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg per day + interferon beta-1a
Number of subjects: 45

Group type: COMPARATOR
Intervention: Interferon beta-1a alone
Number of subjects: 45
Study: 17295573

Group type: EXPERIMENTAL
Intervention: Fluoxetine + Cognitive-Behavioral Therapy (CBT)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Fluoxetine only (Medication-only group)
Number of subjects: 384
Study: 15728784

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with prednisolone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cyclophosphamide followed by azathioprine (CTX-AZA) with prednisolone
Number of subjects: 64
Study: 12353189

Group type: EXPERIMENTAL
Intervention: Valacyclovir 1000 mg twice daily for 1 day
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice daily for 3 days
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Valacyclovir (both regimens)
Number of subjects: 308
Study: 10786413

Group type: EXPERIMENTAL
Intervention: Computer-based refusal skills training
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 188
Study: 7774537

Group type: EXPERIMENTAL
Intervention: Pakistani women
Number of subjects: 58
Study: 1574336

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Theophylline (150 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3893703

Group type: EXPERIMENTAL
Intervention: clebopride (0.5 mg TID)
Number of subjects: 76

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 76
Study: 30948606

Group type: EXPERIMENTAL
Intervention: Hospital at home (HAH) care
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Facilitators of HAH
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Barriers to HAH
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Nurses' perspective on HAH
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Operational concerns regarding HAH
Number of subjects: 89
Study: 29108456

Group type: EXPERIMENTAL
Intervention: Recognition memory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probability manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response payoff manipulation
Number of subjects: 0
Study: 26715086

Group type: EXPERIMENTAL
Intervention: SOSTA-FRA (12 sessions)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 209
Study: 24899339

Group type: EXPERIMENTAL
Intervention: Intervention group with control measures (mixer lid, divider oil, focused training)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Use of mixer lid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Use of divider oil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Focused training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of all control measures
Number of subjects: 30
Study: 22571813

Group type: EXPERIMENTAL
Intervention: Routine-repeat CT group (n = 89)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Non-routine-repeat CT group (n = 82)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Routine-repeat CT group (mild TBI)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Routine-repeat CT group (moderate and severe TBI)
Number of subjects: 171
Study: 19641919

Group type: EXPERIMENTAL
Intervention: Intravenous temozolomide (150 mg/m2 as a 90-min infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral temozolomide (200 mg/m2 on days 1, 2, and 5; 150 mg/m2 on days 3 and 4)
Number of subjects: 0
Study: 18593390

Group type: EXPERIMENTAL
Intervention: NPWT-instillation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard moist wound-care therapy
Number of subjects: 15
Study: 16821205

Group type: COMPARATOR
Intervention: Group B (menopausal women)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Group C (normally menstruating women)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Group A (premature ovarian failure)
Number of subjects: 15
Study: 12568976

Group type: EXPERIMENTAL
Intervention: 600 mg/die valerian extract LI 156 (Sedonium)
Number of subjects: 202

Group type: COMPARATOR
Intervention: 10 mg/die oxazepam
Number of subjects: 202
Study: 9780763

Group type: EXPERIMENTAL
Intervention: 3‐in‐1 block with 40 mL of 1.5% mepivacaine (T group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subarachnoid puncture with 3 mL of 2% lidocaine (S group, n = 20)
Number of subjects: 40
Study: 7932518

Group type: EXPERIMENTAL
Intervention: Lisinopril (20-40 mg daily)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Diltiazem SR (120-180 mg twice daily)
Number of subjects: 110
Study: 3219879

Group type: EXPERIMENTAL
Intervention: Combination inhaler of salbutamol (800 micrograms) and beclomethasone dipropionate (400 micrograms)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Separate inhalers of salbutamol (800 micrograms) and beclomethasone dipropionate (400 micrograms)
Number of subjects: 39
Study: 29330194

Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 250 mg tid
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 500 mg tid
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 26756383

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of a dexamethasone implant (IVI‐DEX) after switching from bevacizumab (AD group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bevacizumab followed by intravitreal injection of a dexamethasone implant (DA group)
Number of subjects: 48
Study: 25316130

Group type: EXPERIMENTAL
Intervention: Pirfenidone therapy (600 mg/day for 8 weeks) with add-on rikkunshi-to from week 4
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Rikkunshi-to
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pirfenidone therapy (1200 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Assessment of plasma levels of acyl-ghrelin and des-acyl-ghrelin, serum KL-6 and surfactant protein-D, and pulmonary function tests
Number of subjects: 17
Study: 23508526

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system (≤ 16 mg/24 h)
Number of subjects: 381
Study: 20117910

Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration (Gr B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo infiltration (Gr P)
Number of subjects: 0
Study: 18259028

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (1 mg/d)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Enalaprilat (0.33 microg/min/100 mL forearm volume)
Number of subjects: 14
Study: 16736149

Group type: EXPERIMENTAL
Intervention: Navigation (using Stryker, Orthopilot, and Navitrack systems)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual instrumentation
Number of subjects: 0
Study: 14603216

Group type: EXPERIMENTAL
Intervention: Reversed saphenous vein (SV) graft
Number of subjects: 51

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) graft
Number of subjects: 51
Study: 10958090

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia with 8 mg hyperbaric bupivacaine 0.5%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bilateral spinal anesthesia with 8 mg hyperbaric bupivacaine 0.5%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bilateral spinal anesthesia
Number of subjects: 100
Study: 8881622

Group type: EXPERIMENTAL
Intervention: Reinforced laryngeal mask airway (LMA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nasotracheal tube
Number of subjects: 100
Study: 8449845

Group type: EXPERIMENTAL
Intervention: Perioperative antibiotic prophylaxis (cephalosporins used in 86% of cases)
Number of subjects: 2587

Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 2587
Study: 3780688

Group type: COMPARATOR
Intervention: 5.0% enflurane in 50% N2O (group E50)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3.2% enflurane in 70% N2O (group E70)
Number of subjects: 30
Study: 31380688

Group type: EXPERIMENTAL
Intervention: OurRelationship program
Number of subjects: 213

Group type: COMPARATOR
Intervention: 2-month waitlist condition
Number of subjects: 213
Study: 29237204

Group type: EXPERIMENTAL
Intervention: Aggressive intravenous hydration with lactated Ringer's solution (3 mL/kg/h during ERCP, a 20-mL/kg bolus, and 3 mL/kg/h for 8 hours after ERCP)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Aggressive intravenous hydration with normal saline solution (3 mL/kg/h during ERCP, a 20-mL/kg bolus, and 3 mL/kg/h for 8 hours after ERCP)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Standard intravenous hydration with lactated Ringer's solution (1.5 mL/kg/h during and for 8 hours after ERCP)
Number of subjects: 395
Study: 28404092

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 25 mg
Number of subjects: 426

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300 mg
Number of subjects: 426
Study: 23864247

Group type: EXPERIMENTAL
Intervention: Presence of bacterial biofilms (study group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No presence of bacterial biofilms (control group)
Number of subjects: 80
Study: 22281609

Group type: EXPERIMENTAL
Intervention: 60 mg/kg emodin
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: 700 mg/kg vitamin C (Vc)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: 60 mg/kg emodin + 700 mg/kg vitamin C (Vc)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (basal diet with 50.3 mg/kg Vc)
Number of subjects: 1200
Study: 20551583

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution (ORS)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Free-choice of their favorite drink (FAD)
Number of subjects: 153
Study: 18514746

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.3 mg subcutaneous)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg oral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine with Donepezil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16422894

Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 12734150

Group type: EXPERIMENTAL
Intervention: CSL 1.5 mL.kg(‐1) per hour fasting duration
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CSL 1.5 mL.kg(‐1) per hour fasting duration with 0.5 g.kg(‐1) dextrose added
Number of subjects: 120

Group type: COMPARATOR
Intervention: No iv fluid (control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CSL/dextrose vs control
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CSL/dextrose vs CSL and control
Number of subjects: 120
Study: 10599721

Group type: COMPARATOR
Intervention: recombinant human GH (rhGH) 6.25 microg/kg LBM for 1 month, 12.5 microg/kg LBM thereafter
Number of subjects: 28

Group type: COMPARATOR
Intervention: recombinant human GH (rhGH)
Number of subjects: 28
Study: 7579030

Group type: EXPERIMENTAL
Intervention: Caffeine (60 mg)
Number of subjects: 10
Study: 1936347

Group type: EXPERIMENTAL
Intervention: Ultrasonic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6999349

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 30371854

Group type: EXPERIMENTAL
Intervention: Forced awakenings (FA) -200 min sleep time
Number of subjects: 79

Group type: COMPARATOR
Intervention: Undisturbed sleep (US)
Number of subjects: 79
Study: 26773557

Group type: EXPERIMENTAL
Intervention: IDegAspSimple titration algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: IDegAspStepwise titration algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: IDegAspStepwise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDegAspSimple
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDegAspSimple and IDegAspStepwise
Number of subjects: 0
Study: 26093487

Group type: EXPERIMENTAL
Intervention: Effect-site remifentanil concentration before bolus administration
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Effect-site remifentanil concentration at spontaneous vaginal delivery
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Effect-site remifentanil concentration during the third quarter
Number of subjects: 23
Study: 23216875

Group type: EXPERIMENTAL
Intervention: Low effect-site concentration of propofol (1.5-2.5 μg/mL)
Number of subjects: 121

Group type: COMPARATOR
Intervention: High effect-site concentration of propofol (3.0-4.0 μg/mL)
Number of subjects: 121
Study: 21239082

Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided needle aspiration
Number of subjects: 101

Group type: COMPARATOR
Intervention: Incision and drainage
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided needle aspiration in patients with CA‐MRSA
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Incision and drainage in patients with CA‐MRSA
Number of subjects: 101

Group type: COMPARATOR
Intervention: Ultrasonographically guided needle aspiration versus incision and drainage in patients with CA‐MRSA
Number of subjects: 101

Group type: COMPARATOR
Intervention: Incision and drainage versus ultrasonographically guided needle aspiration
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Incision and drainage in patients without CA‐MRSA
Number of subjects: 101
Study: 18680213

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional medications
Number of subjects: 108
Study: 16601984

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drug for 2 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: No anti-inflammatory drug (control)
Number of subjects: 38
Study: 14562669

Group type: EXPERIMENTAL
Intervention: Beta blocker therapy
Number of subjects: 2894

Group type: COMPARATOR
Intervention: No beta blocker therapy (Control)
Number of subjects: 2894
Study: 11033985

Group type: EXPERIMENTAL
Intervention: Medium Chain Triglycerides (MCT)
Number of subjects: 12
Study: 8782139

Group type: EXPERIMENTAL
Intervention: Exercise program (aerobic, flexibility, and strengthening elements), 3 times per week for 6 weeks, 1 hour each session.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Relaxation group, 3 times per week for 6 weeks, 1 hour each session.
Number of subjects: 60
Study: 1476277

Group type: EXPERIMENTAL
Intervention: Continuous i.v. infusion of 1 mg.kg‐1 of morphine (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous i.v. infusion of 2 mg.kg‐1 of morphine (group 3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: i.v. boluses of 2 mg of morphine (group 1)
Number of subjects: 30
Study: 6144620

Group type: EXPERIMENTAL
Intervention: Nitrefazole 800 mg (4 capsules of 200 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (4 capsules of identical appearance)
Number of subjects: 62
Study: 30148432

Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol 100,000 IU)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 28482641

Group type: EXPERIMENTAL
Intervention: Bryostatin (25 μg/m2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 9
Study: 25964310

Group type: EXPERIMENTAL
Intervention: Individualized cooling at 0.5°C below body temperature
Number of subjects: 73